



**The UAB Institutional Biosafety Committee Meeting Minutes  
Research Involving Recombinant and Synthetic Nucleic Acid Molecules  
December 08, 2025 12:30 pm**

<b>Members</b>	<b>Present (Y/N)</b>	<b>Vote (Y/N)</b>
1. Joel N. Glasgow, PhD, Chair [JNG]	Y	Y
2. Megan Kiedrowski, PhD, Vice-Chair [MRK]	Y	Y
3. Donna Williamson, MS, RSS [DSW]	Y	Y
4. Amanda F. Smith, BS, RSS, Voting Contact [AFS]	Y	N
5. Cameron Crosby, MD, OM [JCC]	N	N
6. Julie Allen, DNP, OM [JSA]	Y	Y
7. Lillie Flood, RN-BSN, JCDH [LF]	Y	Y
8. Qiang (John) Ding, PhD, VA [QJD]	Y	Y
9. Andrea Osborne, DVM, ARP [AJO]	Y	Y
10. Justin Roth, PhD, BSO-EHS [JCR]	Y	N
11. Brian Lagory, BS, BSO-EHS [BEL]	Y	Y
12. Vineel Reddy, PhD, EHS [VPR]	N	N
13. Julie Gray, BS, EHS [JDG]	Y	Y
14. Tyler Uzzell, MA, IRB [TWU]	Y	Y
15. Amanda J. Watts, MS, IACUC [AJW]	Y	Y
16. Chad Dunaway, IACUC [CD]	N	N
17. Tyler T. Wright, PhD, Lab Rep [TTW]	N	N
18. Masakazu Kamata, PhD, Lab Rep [MK]	Y	Y
19. Kevin Harrod, PhD, Lab Rep [KH]	N	N
20. Christine M. Wright, PhD, Lab Rep [CMW]	Y	Y
21. Larisa Pereboeva, PhD, Lab Rep [LP]	Y	Y
22. Theresa Strong, PhD, Lab Rep [TVS]	Y	Y
23. Aftab Ahmad, PhD, Lab Rep [AA]	Y	Y
24. Adam McClintock, MBA, HSR [AM]	N	N
25. Wesley Willeford, MD, JCDH [WW]	Y	Y
26. Rebecca Johnstone, RSS, Recording Secretary [RMJ]	Y	N
<b>Total</b>	<b>20</b>	<b>17</b>

**Guests Present**

Laura Caltrider, MS, EHS [LPC]	Caitlyn Sebastian, Biomed Sciences [CS]
Earle Durboraw, MA, ARP [EBD]	Douglas Fox, PhD, SEBLAB [DMF]
Joseph Palmer, PhD, SEBLAB [JP]	Luselyz Ortiz Torres, EHS [LOT]
	Dale Payton, ARP [DP]

The December 08, 2025, Institutional Biosafety Committee (IBC) meeting for Research Involving Recombinant of Synthetic Nucleic Acid Molecules was called to order at 12:31 pm via web-based video conferencing tool by JNG. A quorum was present.

### **Welcome and Introduction of Guests**

JNG welcomed all in attendance.

### **Approval of the November 10, 2025, Minutes**

The November 10, 2025, meeting minutes were distributed in the Committee member packet via email and/or secure cloud storage prior to the meeting. A motion was made to approve the minutes. The motion was seconded. There was one abstention. The minutes were approved.

### **Standing Reports**

- In the News/Regulatory Visits – There were no updates.
- Faculty Senate – There were no updates.
- Veterans Administration – There were no updates.
- Employee Health – There has been an increase in flu this winter, which is a normal trend.
- JCDH – There were no updates.
- IRAP and EHSA – There were no updates.
- Research Safety Updates:
  - PI Arrivals/Departures/UAB Lab Relocations – Arrivals: N/A Departures: N/A
  - Safety Visits – Chemical storage and signage continue to be the top findings for audits.


**New/Old Business** – The Viral Vectors SOP was endorsed. Committee chose to tentatively move the monthly meeting to a new date via Survey Monkey.

**Project Review** - The review and discussion of the following projects included: agent characteristics; types of manipulations planned; verification that the PI and laboratory staff performing the research have been appropriately trained in the safe conduct of the research; and containment control measures to be implemented (biosafety level and any special provisions). Please refer to the attached summary of the Committee review outcome for each project.

**Transgenic Projects** - No transgenic projects were discussed at this meeting.

**Adjournment** - The Chair asked if there were any further questions or comments. Being none, the meeting was adjourned at 1:10 pm. The next meeting date is to be decided.

Respectfully submitted by:



---

Rebecca Johnstone, Recording Secretary  
Research Safety Committees

Project registration documents submitted by the PI indicate UAB Institutional Biosafety Committee (IBC) review and approval is required for the following research activities involving recombinant or synthetic nucleic acid (r/sNA) molecules and/or biohazardous agents. If the nature of the work changes or the listed conditions cannot be met, it is the PI's responsibility to consult with the IBC for additional guidance. It is the PI's responsibility to ensure all individuals listed on the project are enrolled in and compliant with the requirements of UAB Employee Health prior to and for the duration of the work:

Approve	Disapprove	Abstain or Recuse	RSC #	Evaluation
17	--	--	25-206	<p>Luciano Costa; <i>A Phase 1/2, Open-label, Multicenter Study of mRNA-2808 in Participants with Relapsed or Refractory Multiple Myeloma</i></p> <p>Reason for IBC:</p> <ul style="list-style-type: none"> <li>Administration of mRNA encoding GPRC5D, FcRH5, and BCMA to one or more human subjects</li> </ul> <p>The University of Alabama at Birmingham's IBC reviewed the proposed work listed above and has approved the work under the following containment conditions.</p> <ul style="list-style-type: none"> <li>BSL1/ Universal precautions must be used for storage, preparation, and administration of the study drug.</li> <li>Aseptic technique must be used for dosage preparation, via laminar flow hood or a BSC</li> <li>Any unused IP and any potentially contaminated materials will be disposed as medical waste or per the sponsor's instructions.</li> </ul>
17	--	--	25-209	<p>Randall Davis; <i>FCRL Regulation in B Cell Tolerance and Malignancy</i></p> <p>Reason for IBC:</p> <ul style="list-style-type: none"> <li>The in vitro use of replication deficient 2nd generation lentiviral vectors, retroviral vectors, and CRISPR-Cas9 gene editing tools.</li> <li>The in vitro use of (non K12 derived) BL21 E. coli.</li> <li>The administration of rsNA modified human and murine cells to animals.</li> <li>The administration of <i>Streptococcus pneumoniae</i> R36A, a Risk Group 2 organism, to animals.</li> </ul> <p>The University of Alabama at Birmingham's IBC reviewed the proposed work listed above and has approved the work under the following containment conditions.</p> <ul style="list-style-type: none"> <li>BSL2 practices and procedures, including the use of an annually certified biosafety cabinet, will be used for all in vitro work with viral vectors.</li> <li>Dispose of all recombinant BL21 waste as medical waste.</li> <li>ABSL1 practices and procedures will be used for administration of rsNA animal cells to animals.</li> </ul>

				<ul style="list-style-type: none"><li>• The UAB Guidelines for Conducting Human Xenograft Experiments in Mice or ABSL1 practices and procedures will be followed for the administration of human material to animals, as applicable.</li><li>• ABSL2 practices and procedures, including the use of an annually certified biosafety cabinet, shall be used for all in vivo work with <i>Streptococcus pneumoniae</i>.</li><li>• The Animal Resources Program will be notified, via the posting of an AUSI, of <i>Streptococcus pneumoniae</i> infected animals.</li><li>• An agent-specific safety and data plan will be made available and reviewed by all personnel working with <i>Streptococcus pneumoniae</i>.</li></ul>
--	--	--	--	---